Search this site

Omada Health v Hinge Health Health v Doctolib financials and IPO prospects Omada Health v Hinge Health v Doctolib financials and IPO prospects Omada Health, Hinge Health, and Doctolib are digital health unicorns with B2B, employer-focused models, leveraging AI and technology to drive strong revenue growth. They’re positioned for IPOs in 2025, capitalising on a resilient healthcare market, though Doctolib’s plans remain speculative. Their shared focus on scalable, tech-driven healthcare solutions and significant funding underscores their alignment within the evolving digital health landscape. Hinge Health leads with a concrete IPO plan, strong financials, and a focused MSK model, making it the most advanced and likely to succeed in the near term. Its $437M raise and $2.42B–$2.9B valuation provide clarity. Omada Health is a strong contender with a broader platform and growing revenue, but its losses and lack of raise details temper expectations motional appeal may limit its upside. Its Amazon partnership adds credibility. Doctolib remains speculative without a filing, but its European dominance positions it as a potential IPO candidate. Investors should await confirmed data. Below is a comparative analysis of Omada Health, Doctolib, and Hinge Health, focusing on their financials and IPO prospects based on available public information. Note that financial data for private companies like these is often limited and Doctolib's financials are less publicly detailed compared to Omada Health and Hinge Health, which have recently filed for IPOs. 1. Omada Health Omada Health is a San Francisco-based digital health company founded in 2011, specializing in virtual chronic care programs for conditions like diabetes, hypertension, obesity, and musculoskeletal (MSK) issues. It combines AI-driven tools, connected devices, and human coaching to deliver personalised care, primarily to employers, health plans, and pharmacy benefit managers (PBMs). Financials: Revenue: 2023: $122.8 million 2024: $169.8 million (38% YoY growth) Q1 2025: $55 million (57% YoY growth from $35.1 million in Q1 2024) Net Loss: 2023: $67.5 million 2024: $47.1 million (narrowed by 30%) Q1 2025: $9.4 million (down from $19 million in Q1 2024) Gross Margin: 60% in Q1 2025 Funding: Raised $529.67 million over 14 rounds, with a $1.02 billion valuation in February 2022 (Series E). However, its Forge Price (private market valuation metric) dropped 37% to $4.14 per share by early 2024, though it rebounded 45% from 2023 lows. Customer Concentration Risk: 69% of 2024 revenue came from its top five health plan and PBM customers, posing a risk if key contracts are lost. IPO Prospects: Status: Omada filed for an IPO on May 9, 2025, to list on Nasdaq under the ticker “OMDA,” aiming to raise up to $100 million. Strengths: Strong revenue growth and narrowing losses signal improving financial health. Serves over 2,000 customers and 679,000 members, with partnerships like Amazon and CVS Caremark enhancing credibility. Operates in a high-demand market, with chronic conditions accounting for 90% of U.S. healthcare spending ($3.7 trillion annually). Backed by reputable underwriters (J.P. Morgan, Goldman Sachs, Morgan Stanley, Barclays). Challenges: Unprofitability and reliance on a few major clients (69% of revenue) raise concerns. Valuation volatility in private markets may temper investor confidence. Competitive pressure from Hinge Health, Sword Health, and others in the digital health space. The IPO market for digital health has been tepid since 2023, with no digital health IPOs in 2023 and only $7.1 billion raised in 2024 (up from $2.8 billion in 2023). Omada’s IPO is a test of investor appetite for digital health post-pandemic. Its focus on chronic care and strong growth make it a compelling candidate, but profitability and client diversification are critical for success. Timing may benefit from improving market conditions in 2025, post-U.S. election. 2. Doctolib Doctolib, founded in 2013 and headquartered in Paris, France, is a leading European digital healthcare platform that connects patients with healthcare providers. It offers online appointment booking, telemedicine, and medical document-sharing services. Doctolib operates primarily in France, Germany, and Italy, with a growing international presence. Financials: Revenue: Limited public data is available, as Doctolib remains privately held and has not filed for an IPO. In 2022, Doctolib reported €250 million (~$270 million USD) in annual recurring revenue, with 30% YoY growth. No 2023–2025 financials are publicly disclosed. [Source: Doctolib press releases, 2022] Profitability: Doctolib has stated it is not yet profitable, focusing on reinvestment for growth. No specific loss figures are available. Funding: Raised €800 million ($860 million USD) across multiple rounds, with a €5.8 billion ($6.2 billion USD) valuation in 2022, making it one of Europe’s most valuable health tech startups. Investors include Bpifrance, Eurazeo, and General Atlantic. [Source: Crunchbase] Customer Base: Serves 80 million patients and 900,000 healthcare professionals across Europe, with 300,000 daily appointments booked. IPO Prospects: Status: No confirmed IPO filing as of May 15, 2025. Doctolib has been named a potential IPO candidate for 2024–2025 due to its market leadership and growth, but no concrete plans have been announced. Strengths: Dominant player in Europe’s digital health market, with a scalable platform and strong brand recognition. High valuation and significant funding provide financial flexibility. Operates in a growing market, with Europe’s healthcare digitisation lagging behind the U.S., offering room for expansion. Challenges: Lack of transparency on recent financials makes it hard to assess current performance. No IPO filing suggests caution, possibly due to market volatility or a preference for private funding. Regulatory complexities in Europe’s fragmented healthcare systems could complicate scaling. Competition from regional players and U.S.-based telehealth companies entering Europe. Doctolib’s IPO potential hinges on market conditions and its ability to demonstrate profitability or a clear path to it. While it’s a strong candidate due to its scale and market position, the absence of a filing suggests it may wait until 2026 or later, especially given the cautious IPO environment for health tech. 3. Hinge Health Hinge Health, founded in 2014 and based in San Francisco, provides digital musculoskeletal (MSK) care, including virtual physical therapy and pain management. It uses AI-powered motion tracking, wearable devices (e.g., Enso), and human therapists to deliver personalised care, primarily to employers like Lyft, Target, and GM. Financials: Revenue: 2024: Not explicitly stated, but revenue for the 12 months ended March 31, 2025, was $432 million (33.4% YoY growth reported for 2024). Q1 2025: $123.8 million Net Loss: 2024: Reduced, but specific figures not disclosed in available data. Historical context: Hinge has not achieved annual profitability, similar to Omada. Gross Margin: 81% in Q1 2025, significantly higher than Omada’s 60%. Funding: Raised over $1 billion, with a $6.2 billion valuation in 2021 (Series E led by Tiger Global and Coatue Management). Customer Base: Serves over 1 million patients, covered by 50+ health plans, with 2,500 employer clients. IPO Prospects: Status: Hinge Health filed for an IPO on March 10, 2025, and plans to raise up to $437 million, targeting a $2.6 billion valuation. It will list on the NYSE under the ticker “HNGE,” with pricing expected the week of May 19, 2025. Strengths: Strong revenue ($432 million) and high gross margin (81%) reflect operational efficiency. Reduced net losses and a 33.4% revenue increase in 2024 show financial improvement. Large client base and partnerships with major employers enhance market credibility. Backed by 14 banks, including Morgan Stanley, Barclays, and BofA Securities, signalling strong institutional support. MSK care is a growing market, with 50% of adults affected by joint/muscle pain. Challenges: Valuation ($2.6 billion) is significantly lower than its 2021 peak ($6.2 billion), which may concern investors. Faces competition from Omada, Sword Health, Kaia Health, and others in the virtual MSK space. The digital health IPO market remains volatile, with recent stagnation (no IPOs in 2023). Hinge’s IPO is a bellwether for digital health, following a two-year IPO drought. Its higher revenue and margins give it an edge over Omada, but the lower valuation and competitive landscape are hurdles. Success depends on proving scalability and capitalising on renewed investor interest in healthcare tech (2024 saw $7.1 billion in U.S. healthcare IPOs). Comparative Summary Metric Omada Health Doctolib Hinge Health Focus Chronic care (diabetes, hypertension, MSK) Healthcare booking/telemedicine Musculoskeletal care (virtual PT) Revenue (Latest) $169.8M (2024); $55M (Q1 2025) ~$270M (2022, no recent data) $432M (12M to Mar 2025); $123.8M (Q1 2025) Revenue Growth 38% YoY (2024); 57% YoY (Q1 2025) 30% YoY (2022, no recent data) 33.4% YoY (2024) Net Loss (Latest) $47.1M (2024); $9.4M (Q1 2025) Not profitable, no figures disclosed Reduced (2024, no specific figure) Gross Margin (Q1 2025) 60% Not available 81% Funding $529.67M, $1.02B valuation (2022) $860M, $6.2B valuation (2022) $1B+, $6.2B valuation (2021) IPO Status Filed May 2025, Nasdaq “OMDA” No filing, potential 2024–2025 candidate Filed Mar 2025, NYSE “HNGE” IPO Target $100M Not applicable $437M, $2.6B valuation Key Risk Client concentration (69% from top 5) Lack of financial transparency Lower valuation vs. 2021 peak Market Opportunity $3.7T U.S. chronic care market Growing EU healthcare digitization 50% of adults with MSK issues Financial Comparison: Hinge Health leads in revenue ($432M vs. Omada’s $169.8M) and gross margin (81% vs. 60%), reflecting stronger operational efficiency. Its $437M IPO target dwarfs Omada’s $100M, but its valuation ($2.6B) is lower than its 2021 peak ($6.2B). Omada Health shows faster revenue growth (38% vs. 33.4% YoY in 2024) and a clearer path to reducing losses, but its client concentration risk is a concern. Doctolib’s financials are opaque, with only 2022 data available (~$270M revenue). Its high valuation ($6.2B) suggests scale, but lack of recent metrics or IPO plans limits comparability. IPO Prospects: Hinge Health is the furthest along, with a filing in March 2025 and pricing imminent (May 19, 2025). Its larger revenue base and high margins position it as a stronger candidate, though valuation concerns linger. Omada Health’s May 2025 filing follows Hinge, capitalizing on similar market momentum. Its chronic care focus aligns with a massive market, but profitability and client diversification are critical. Doctolib lags, with no IPO filing despite speculation. Its European focus and lack of financial transparency make it a less immediate prospect, likely waiting for better market conditions. Market Context: The digital health IPO market has been dormant since 2021 (20 IPOs) and 2022 (2 IPOs), with none in 2023. A 2024 rebound ($7.1B raised) suggests improving sentiment, but volatility and post-election uncertainty could impact 2025 outcomes. All three face competition (e.g., Sword Health, Kaia Health for Hinge/Omada; regional telehealth platforms for Doctolib) and regulatory/reimbursement risks. Conclusion Hinge Health is the strongest IPO candidate due to its higher revenue, margins, and advanced IPO timeline. However, its reduced valuation requires investor confidence in future growth. Omada Health is a close second, with robust growth and a clear chronic care niche, but it must address client concentration and profitability to succeed publicly. Doctolib remains speculative, with no IPO filing and limited financial data. Its European dominance is promising, but it may delay going public until market conditions improve. For investors, Hinge offers the most immediate opportunity, followed by Omada, while Doctolib is a longer-term watch. Both Hinge and Omada’s IPOs will test the digital health market’s revival, with outcomes likely influencing Doctolib’s strategy. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025 HIMSS AI in Healthcare > 10-11th July 2025

How do HealthTech founders solve the Long Sales Cycle problem in Healthcare? How do HealthTech founders solve the Long Sales Cycle problem in Healthcare? HealthTech founders face long sales cycles in healthcare due to complex decision making processes, regulatory requirements, and risk averse stakeholders like hospitals, NHS Trusts insurers and government bodies. Sales cycles can range from 6 months to over 2 years, especially for enterprise solutions targeting NHS trusts or large providers. Below are 10 strategies HealthTech founders can use to address these challenges based on Nelson Advisors 10+ years of experience selling healthcare technology solutions. 1. Understand and Navigate the Stakeholder Landscape The NHS and private healthcare systems involve diverse stakeholders (clinicians, procurement teams, IT departments, finance, and C-suite executives) with different priorities. Mapping these stakeholders early prevents delays from misaligned pitches or approvals. How to Implement: Conduct stakeholder mapping to identify decision-makers, influencers, and gatekeepers (e.g., clinical leads, NHS trust CEOs, or integrated care system managers). Tailor value propositions to each group: cost savings for finance, workflow efficiency for clinicians, and data security for IT. Engage early with NHS innovation hubs (e.g., NHS England’s Innovation Service or Academic Health Science Networks) to understand procurement pathways. Example: Healthtech-1 (founded 2023), a UK startup automating GP practice administration, shortened its sales cycle by targeting practice managers first, demonstrating immediate time savings, which secured buy-in from GP partners faster. 2. Leverage Pilot Programs and Proof-of-Concept Studies Small-scale pilots or proof-of-concept (PoC) trials allow healthcare providers to test solutions with minimal risk, generating real-world evidence that accelerates trust and adoption. How to Implement: Offer low-cost or subsidised pilots to NHS trusts or private clinics, focusing on a single department or use case. Collect quantitative data (e.g., time saved, cost reduction, patient outcomes) and qualitative feedback (e.g., clinician satisfaction) during pilots. Use pilot results to build case studies that address stakeholder concerns, making it easier to scale to larger contracts. Example: Lindus Health (founded 2021) accelerated adoption by running pilots for its clinical trial platform with smaller biotech firms, proving 3x faster trial timelines, which led to faster enterprise contracts. 3. Focus on Quick-Win Solutions with Clear ROI Solutions that deliver immediate, measurable benefits (e.g., cost savings, reduced admin time) are more likely to gain traction than those requiring long-term validation or cultural shifts. How to Implement: Develop lean MVPs targeting specific pain points (e.g., appointment scheduling, patient triage) that don’t require extensive integration or regulatory hurdles. Quantify ROI in proposals (e.g., “saves 10 hours of clinician time per week” or “reduces no-show rates by 20%”). Prioritise solutions that align with NHS priorities, such as reducing waiting lists or improving primary care efficiency. Example: Healthtech-1 focused on automating patient registration, a low-hanging fruit for GP practices, showing immediate time savings, which shortened sales cycles compared to broader practice management tools. 4. Build Strategic Partnerships Partnering with established healthcare players (e.g., EHR vendors, consultancies, or existing NHS suppliers) provides credibility, access to networks, and faster integration into workflows, bypassing lengthy vetting processes. How to Implement: Partner with EHR providers like EMIS or SystmOne to ensure interoperability, making adoption seamless. Collaborate with consultancies (e.g., Deloitte, Accenture) that advise NHS trusts on digital transformation. Join accelerator programs like DigitalHealth.London , which connect startups with NHS decision-makers. Example: Cogs AI (founded 2022) partnered with NHS trusts through DigitalHealth.London ’s accelerator, gaining direct access to mental health leads, which expedited pilot deployments and contracts. 5. Invest in Clinical Validation and Evidence Healthcare buyers, especially the NHS, require robust evidence of efficacy, safety, and cost-effectiveness. Early investment in clinical studies or real-world data reduces delays during procurement. How to Implement: Conduct small-scale studies with academic partners or NHS trusts to generate peer-reviewed data. Align with NICE (National Institute for Health and Care Excellence) evidence standards for digital health technologies. Use real-world evidence from early adopters to build credibility for larger contracts. Example: MindSens (founded 2022) invested in early dementia screening trials with UK universities, producing data that convinced NHS trusts to fast-track evaluations, shortening the sales cycle. 6. Adopt a Consultative Sales Approach Healthcare buyers value partners who understand their challenges and co-create solutions, rather than pushing generic products. A consultative approach builds trust and aligns solutions with buyer needs. How to Implement: Train sales teams to act as advisors, focusing on listening to stakeholder pain points rather than pitching features. Offer workshops or discovery sessions to co-design solutions with clinicians and managers. Provide flexible pricing models (e.g., subscription-based or pay-per-outcome) to reduce financial barriers. Example: Flo Health (significant growth 2020–2025) engaged women’s health clinicians in co-designing app features, building trust that led to faster partnerships with private UK clinics. 7. Target Non-NHS Markets Initially Why It Helps: The NHS’s slow procurement can be bypassed by targeting private healthcare providers, insurers, or direct-to-consumer markets, which often have shorter sales cycles and can provide traction for later NHS deals. How to Implement: Sell to private hospitals (e.g., Bupa, HCA) or insurers (e.g., AXA, Vitality) that have more flexible budgets. Launch consumer-facing products (e.g., wellness apps, wearables) to build a user base and revenue stream. Use private sector success as a case study to approach NHS buyers. Example: Dotplot (founded 2022) targeted direct-to-consumer sales for its breast health monitoring device, building a user base and brand recognition that later attracted NHS interest for pilot programs. 8. Streamline Regulatory and Procurement Alignment Missteps in regulatory compliance (e.g., MHRA, UKCA) or failure to meet NHS procurement frameworks (e.g., G-Cloud, Dynamic Purchasing Systems) can delay sales. Early alignment prevents rework. How to Implement: Hire regulatory consultants to ensure compliance with MHRA and GDPR requirements from day one. Register on NHS procurement platforms like the NHS Supply Chain or G-Cloud to streamline bidding. Achieve certifications like ISO 27001 for data security to boost credibility. Example: Untap Health (founded 2021) prioritised ISO 27001 certification for its sewage-testing tech, enabling faster inclusion in public health tenders. 9. Hire Healthcare-Experienced Sales Talent Sales professionals with NHS or healthcare experience understand procurement nuances, stakeholder dynamics, and jargon, enabling faster relationship-building and deal closure. How to Implement: Recruit sales leads with a track record in healthtech or medtech, ideally with NHS contacts. Train teams on NHS-specific sales frameworks, such as the NHS Commercial Framework. Leverage advisors or non-executive directors with healthcare sales experience to open doors. Example: Insight Surgery (founded 2023) hired a former NHS trust executive as a sales advisor, leveraging their network to secure early meetings with surgical departments. 10. Lead with evidence based marketing Healthacre stakeholders are becoming more skeptical of the continous marketing material based around operational efficiencies and productivity benefits. Lead with clear evidence based features and benefits to build trust and credibility in a short period of time. How to Implement: Reference your evidence and the impact your product or service is having over a 3, 6 or 12 month cycle Educate potential buyers on the clinical, operational, financial and patient benefits they can expect. Model the short term and long term impact customers can expect. Example: Zesty (founded 2012) designed all of their NHS focused marketing campaigns targeting new customers for their integrated hopsital patient portal based on evidence they generated at Milton Keynes University Hospital NHS Trust and Guy's and St Thomas NHS Trust. Key Takeaways from 10 Recommendations Prioritise Relationships: Engage stakeholders early, co-create solutions, and build trust through pilots and evidence. Focus on Speed: Target quick wins, private markets, or streamlined regulatory paths to show traction. Leverage Networks: Use partnerships, accelerators, and experienced hires to bypass bureaucratic delays. Data is King: Robust clinical and economic evidence accelerates buyer confidence. NHS-Specific Context: The NHS’s 2023/24 budget constraints and focus on digital transformation (e.g., NHS Long Term Plan) mean solutions tied to cost savings or waiting list reductions are prioritised. Private Sector Advantage: Private providers in the UK (e.g., Bupa) often have 6–12 month sales cycles, making them a faster entry point. Scalability: Strategies like pilots and partnerships can scale to international markets, where sales cycles may be shorter (e.g., US private healthcare). Metrics to Track Progress Time to Pilot: Aim for pilots within 3–6 months of initial outreach. Stakeholder Meetings: Secure meetings with at least 2–3 stakeholder groups (e.g., clinical, finance, IT) within 2 months. Conversion Rate: Track how many pilots convert to full contracts (aim for 50%+ with strong evidence). Sales Cycle Length: Benchmark against industry averages (12–18 months for NHS) and aim to reduce by 20–30% with strategies above. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Hinge Health and Omada Health IPOs set to increase HealthTech M&A multiples by boosting sector confidence Hinge Health and Omada Health IPOs set to increase HealthTech M&A multiples by boosting sector confidence The Hinge Health and Omada Health IPOs, filed in March and May 2025 respectively, are poised to increase HealthTech M&A multiples by signalling strong investor confidence in digital health. These IPOs, among the first major ones in the sector after a two-year drought, highlight the appeal of digital health solutions like musculoskeletal care and chronic condition management. This renewed optimism could drive acquirers to pay higher multiples for similar HealthTech firms, especially those with scalable SaaS or value-based care models. Increased Investor Confidence and Sentiment Validation of Business Models: Successful IPOs of prominent digital health companies like Hinge Health and Omada Health can validate the viability and scalability of virtual care models, particularly in areas like musculoskeletal (MSK) care and chronic disease management. This success can signal to investors that these companies have navigated the challenges of growth, patient engagement, and achieving meaningful outcomes. Positive Market Signal: A strong performance in the public markets for Hinge Health and Omada Health would send a positive signal to the broader investment community regarding the potential of HealthTech companies. This can attract more capital into the sector, both for public and private investments, including M&A activities. Reduced Perceived Risk: Successful IPOs can reduce the perceived risk associated with investing in HealthTech, especially in digital health solutions. This could make acquirers more willing to pay higher multiples for promising targets. Benchmarking and Valuation Anchors Establishing Public Comparables: The IPOs will create publicly traded comparable companies for valuation purposes. The trading multiples (e.g., EV/Revenue, EV/Gross Profit) of Hinge Health and Omada Health post-IPO will serve as benchmarks for valuing other private HealthTech companies, potentially leading to upward adjustments in M&A deals. Increased Price Discovery: The public market will provide a more transparent valuation for these types of businesses, which can influence private market valuations and M&A negotiations. Sellers may point to the public market valuations to justify higher acquisition prices. Strategic Implications for Acquirers Fear of Missing Out (FOMO): If Hinge Health and Omada Health perform well in the public market, potential acquirers might feel pressure to act quickly and secure similar assets before valuations potentially increase further. Enhanced Strategic Rationale: The success of these IPOs can strengthen the strategic rationale for acquisitions in the digital health space. Incumbent healthcare players (payers, providers, pharma) may look to acquire companies like Hinge Health or Omada Health, or their competitors, to enhance their digital capabilities, expand their service offerings, and improve patient outcomes and cost efficiency. Availability of Capital: Publicly traded companies that see their valuations increase post-IPO may also have more capital (through equity or debt) to pursue strategic acquisitions, further driving M&A activity and potentially higher multiples. Current HealthTech M&A Landscape and Multiples While specific M&A multiples fluctuate based on various factors (company growth rate, profitability, market segment, etc.), the HealthTech sector has generally seen healthy M&A activity. Recent trends indicate that acquirers are increasingly prioritising companies with strong recurring revenue, clear paths to profitability, and innovative technologies, particularly in areas like AI, telehealth, and data analytics. As of early 2025, average revenue multiples for HealthTech companies were reported to be in the range of 4-6x, with potential for higher multiples for companies demonstrating exceptional growth or strategic value. The successful IPOs of Hinge Health and Omada Health could push the higher end of this range upwards, especially for companies with similar profiles. Recent HealthTech IPOs as Precedents While the digital health IPO market experienced a slowdown after a surge in 2021, there have been some notable IPOs in the recent past, such as Waystar and Tempus AI in 2024. The performance of these IPOs, along with the upcoming ones, will be closely watched by the market. Omada Health itself filed for an IPO in May 2025, indicating a potential revival in digital health IPO activity. The anticipated IPOs of Hinge Health and Omada Health have the potential to inject significant optimism into the HealthTech sector. Their performance in the public markets will likely serve as a barometer for investor sentiment and could lead to increased M&A activity at potentially higher valuation multiples as both strategic and financial buyers look to capitalise on the demonstrated success and future potential of digital health solutions. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

HealthBench: OpenAI’s first major Healthcare AI initiative HealthBench: OpenAI’s first major Healthcare AI initiative HealthBench is an open-source benchmark developed by OpenAI, released on May 12th, 2025 to evaluate the performance and safety of large language models (LLMs) in healthcare contexts. It was created with input from over 250 physicians across 60 countries to ensure clinical relevance. Key features include: Dataset: 5,000 multi-turn, realistic health conversations covering 26 medical specialties (e.g., cardiology, Paediatrics) and 49 languages, including underrepresented ones like Amharic and Nepali. Evaluation: 48,562 evaluation points scored by GPT-4.1, based on physician-written rubrics assessing accuracy, context, completeness, and safety in tasks like triage, diagnosis, and patient communication. Tasks: Scenarios range from handling emergencies (e.g., advising on an unresponsive 70-year-old patient) to routine care (e.g., managing diabetes follow-ups). Responses are scored on correctness and appropriateness (e.g., recommending emergency services or checking airways). Performance: OpenAI’s o3 model led with a 60% score, followed by xAI’s Grok at 54% and Google’s Gemini 2.5 Pro at 52%. Scores reflect alignment with clinical standards. Availability: Accessible via OpenAI’s GitHub repository for researchers and developers to test and improve LLMs. HealthBench aims to standardise LLM evaluation in healthcare, addressing gaps in reliability and safety by providing a transparent, physician-validated framework. Potential for Healthcare AI Healthcare AI, particularly LLMs, has transformative potential, but it also faces challenges. HealthBench highlights both opportunities and areas for improvement. Below is an overview of its potential: 1. Clinical Decision Support Potential: AI can assist clinicians by providing rapid, evidence-based recommendations for diagnosis, treatment, or triage. For example, HealthBench scenarios show AI suggesting correct emergency protocols (e.g., calling 911 for an unresponsive patient). Impact: Could reduce diagnostic errors (e.g., misdiagnosis rates, which studies estimate at 5-20% in the U.S.) and support overburdened healthcare systems, especially in low-resource settings. Challenges: HealthBench scores (highest at 60%) indicate AI still misses nuances in complex cases, risking incorrect advice. Human oversight remains critical. 2. Patient Communication and Education Potential: AI can deliver tailored health advice in multiple languages, as seen in HealthBench’s 49-language coverage. It could empower patients with clear explanations of conditions or treatment plans. Impact: Improves health literacy and adherence to treatments, particularly in underserved communities with language barriers. Challenges: AI must avoid overly technical or culturally insensitive responses, which HealthBench rubrics flag as weaknesses in some models. 3. Triage and Telemedicine Potential: AI can prioritise urgent cases in telemedicine or emergency settings, guiding patients to appropriate care levels (e.g., ER vs. primary care). HealthBench tests this through scenarios like stroke symptom assessment. Impact: Enhances efficiency in strained systems (eg. reducing ER wait times, which average 2-3 hours in U.S. hospitals) and expands access in remote areas. Challenges: Errors in triage (e.g., underestimating severity) could be life-threatening. HealthBench shows even top models score below 70% in some cases. 4. Administrative Efficiency Potential: AI can streamline tasks like medical record summarization, billing, or scheduling, freeing clinicians for patient care. HealthBench indirectly supports this by ensuring AI understands clinical contexts. Impact: Could save billions annually (eg. U.S. healthcare spends ~8% of revenue on administration) and reduce physician burnout. Challenges: Requires integration with existing systems and compliance with regulations like HIPAA, not directly addressed by HealthBench. 5. Global Health Equity Potential: Multilingual AI, as tested in HealthBench, can serve diverse populations, including in low-income countries with physician shortages (e.g., sub-Saharan Africa has ~0.2 doctors per 1,000 people vs. 2.6 in the US.) Impact: Bridges gaps in care access, offering scalable solutions for basic health queries or preventive care. Challenges: Limited internet access and cultural differences in healthcare expectations can hinder deployment. 6. Research and Development Potential: HealthBench enables developers to refine LLMs for healthcare, fostering innovation in specialised models (e.g., for rare diseases or personalised medicine). Impact: Accelerates AI-driven drug discovery or predictive analytics, potentially cutting development timelines (e.g., AI has reduced drug screening times by ~30% in some studies). Challenges: Requires robust datasets beyond HealthBench to cover niche areas like genomics or mental health. Limitations and Risks Accuracy Gaps: HealthBench shows no model exceeds 60% alignment with physician standards, indicating risks of errors in high-stakes settings. Bias and Fairness: AI may perpetuate biases in training data (e.g., underrepresenting certain demographics), which HealthBench’s diverse dataset aims to mitigate but doesn’t fully resolve. Regulation: Healthcare AI must comply with strict standards (e.g., FDA oversight in the U.S.), and HealthBench is a research tool, not a regulatory framework. Future Directions Improved Benchmarks: Expanding HealthBench to include more specialties, real-world patient data, or longitudinal care scenarios could enhance its scope. Hybrid Systems: Combining AI with human oversight (e.g., AI drafts, physicians review) could maximise safety and efficiency. Ethical Deployment: Partnerships with global health organisations could ensure equitable AI access while addressing privacy and cultural concerns. HealthBench Abstract We present HealthBench, an open-source benchmark measuring the performance and safety of large language models in healthcare. HealthBench consists of 5,000 multi-turn conversations between a model and an individual user or healthcare professional. Responses are evaluated using conversation-specific rubrics created by 262 physicians. Unlike previous multiple-choice or short-answer benchmarks, Health- Bench enables realistic, open-ended evaluation through 48,562 unique rubric criteria spanning several health contexts (e.g., emergencies, transforming clinical data, global health) and behavioural dimensions(e.g., accuracy, instruction following, communication). HealthBench performance over the last two years reflects steady initial progress (compare GPT-3.5 Turbo’s 16% to GPT-4o’s 32%) and more rapid recent improvements (o3 scores 60%). Smaller models have especially improved: GPT-4.1 nano outperforms GPT-4o and is 25 times cheaper. We additionally release two HealthBench variations: HealthBench Consensus, which includes 34 particularly important dimensions of model behaviour validated via physician consensus, and HealthBench Hard, where the current top score is 32%. We hope that HealthBench grounds progress towards model development and applications that benefit human health. Source: https://cdn.openai.com/pdf/bd7a39d5-9e9f-47b3-903c-8b847ca650c7/healthbench_paper.pdf Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Rubric evaluations: the next frontier in Healthcare AI Rubric evaluations: the next frontier in Healthcare AI Rubric evaluations, as exemplified by OpenAI’s HealthBench, represent a critical advancement in healthcare AI by providing structured, physician-validated frameworks to assess large language models (LLMs). These rubrics, systematic scoring guides that measure accuracy, context, completeness and safety are emerging as the next frontier in healthcare AI. They shift AI development from generic performance metrics to clinically relevant, human-centred evaluations, ensuring models align with real-world medical needs. Below, we explore why rubric evaluations are pivotal, their current role and potential to shape the future of healthcare AI. Why Rubric Evaluations Are the Next Frontier Clinical Relevance Over Generic Metrics Traditional AI benchmarks (e.g., MMLU for general knowledge) don’t capture the nuances of healthcare, where errors can be life-threatening. HealthBench’s rubrics, developed by over 250 physicians, evaluate LLMs on specific tasks like triage or patient communication, scoring responses against clinical standards (eg. recommending emergency services for an unresponsive patient). Example: In HealthBench, a model’s response to a stroke query is scored on accuracy (correct symptoms identified?), context (urgency conveyed?), and completeness (all steps included?). This granular feedback ensures AI meets medical rigour, unlike broad accuracy percentages. Standardising Safety and Trust : Healthcare AI must be safe and reliable to gain trust from clinicians and patients. Rubrics provide transparent, reproducible criteria, reducing subjectivity in evaluations. HealthBench’s 48,562 evaluation points, scored by GPT-4.1 but based on physician input, offer a standardized way to flag errors (e.g., missing a critical triage step). Potential: As rubrics evolve, they could become industry standards, guiding regulatory bodies like the FDA to certify AI tools, similar to how clinical trials validate drugs. Bridging AI and Human Expertise Rubrics incorporate human expertise, ensuring AI aligns with physician judgment rather than replacing it. HealthBench’s physician-written rubrics reflect real-world priorities, like cultural sensitivity or multilingual clarity, which generic AI training might overlook. Example: A rubric might penalise an AI for using technical jargon with a non-English-speaking patient, pushing developers to prioritise patient friendly communication. Driving Iterative Improvement Rubric evaluations provide detailed feedback, enabling developers to pinpoint weaknesses. In HealthBench, OpenAI’s o3 model scored 60%, xAI’s Grok 54%, and Google’s Gemini 2.5 Pro 52%, with rubrics highlighting specific areas (e.g., Grok’s strength in context but weaker completeness). This guides targeted model refinement. Potential: Automated rubric feedback loops could accelerate AI training, making models more robust over time. Current Role in Healthcare AI HealthBench demonstrates rubric evaluations in action: Structure: Each of its 5,000 multi-turn health conversations is assessed using rubrics that score responses across dimensions like accuracy (correct medical advice?), safety (no harmful suggestions?), and empathy (patient-appropriate tone?). For instance, a scenario involving a diabetic patient’s insulin query might score 77% if the AI correctly advises dosage but omits dietary guidance. Scale: Covering 26 specialties and 49 languages, HealthBench’s rubrics ensure broad applicability, testing AI in diverse contexts like rural clinics or multilingual settings. Transparency: Open-sourced on OpenAI’s GitHub, the rubrics allow global researchers to adopt or adapt them, fostering collaboration. Limitations: Current rubrics rely on GPT-4.1 for scoring, which introduces potential bias, and may not cover all healthcare scenarios (e.g., mental health or rare diseases). Human oversight is still needed to validate scores. Potential of Rubric Evaluations in Healthcare AI Rubric evaluations could transform healthcare AI in several ways: Personalised and Equitable Care Potential: Rubrics can evaluate AI’s ability to tailor responses to diverse populations, as HealthBench does with 49 languages. Future rubrics could assess cultural competence or accessibility for disabilities, ensuring AI serves marginalized groups. Impact: Reduces healthcare disparities, especially in regions with low physician density (e.g., 0.2 doctors per 1,000 in sub-Saharan Africa vs. 2.6 in the US.). Example: A rubric could score an AI’s response to a non-English-speaking patient, penalising generic advice and rewarding culturally relevant suggestions. Regulatory and Ethical Standards Potential: Rubrics could form the basis for regulatory frameworks, defining “safe” AI performance. For example, a rubric might require 90% accuracy in triage tasks for FDA approval. Impact: Accelerates deployment of AI tools while ensuring compliance with laws like HIPAA or GDPR, building public trust. Example: Rubrics could be integrated into certification processes, similar to how Joint Commission standards evaluate hospitals. Real-Time Clinical Integration Potential: Rubrics could be embedded in AI systems to provide real-time feedback during clinical use. For instance, an AI assisting a doctor with diagnosis could display a rubric score (e.g., 85% confidence in recommending antibiotics) to guide human decisions. Impact: Enhances AI as a decision-support tool, reducing errors (e.g., misdiagnosis rates of 5-20% in the U.S.) and improving outcomes. Example: A triage chatbot could use rubrics to flag low-confidence responses, prompting escalation to a physician. Expanding Scope and Complexity Potential: Future rubrics could cover advanced tasks like longitudinal care (e.g., managing chronic diseases over months) or interdisciplinary scenarios (e.g., coordinating oncology and cardiology). They could also evaluate multimodal AI (e.g., analyzing medical images alongside text). Impact: Enables AI to handle complex cases, supporting precision medicine or rare disease management. Example: A rubric might assess an AI’s ability to integrate lab results, patient history, and imaging to recommend a cancer treatment plan. Global Collaboration and Scalability Potential: Open-source rubrics, like HealthBench’s, allow global researchers to contribute, creating region-specific or specialty-specific versions. Crowdsourced rubric development could address local healthcare challenges. Impact: Scales AI solutions to low-resource settings, where 50% of the world’s population lacks basic healthcare access. Example: A rubric tailored for rural India could prioritise AI’s ability to handle infectious diseases with limited diagnostic tools. Challenges and Risks Bias in Rubric Design: Rubrics reflect the perspectives of their creators (e.g., HealthBench’s 250 physicians). If not diverse enough, they may overlook certain populations or conditions. Scalability Limits: Creating comprehensive rubrics for all healthcare scenarios is resource-intensive, and HealthBench’s 5,000 cases cover only a fraction of possible interactions. Overreliance on Automation: Using AI (e.g., GPT-4.1) to score rubrics risks propagating errors. Human validation remains essential but costly. Resistance to Adoption: Clinicians may distrust rubric-based AI evaluations if they don’t align with real-world practice or if scores are misinterpreted (e.g., X posts falsely claiming AI outperforms doctors). Future Directions Dynamic Rubrics: Develop adaptive rubrics that evolve with medical guidelines or patient feedback, using real-world data to stay current. Multimodal Integration: Extend rubrics to evaluate AI that processes text, images, and sensor data (e.g., wearables), ensuring holistic assessments. Patient Centred Metrics: Include patient satisfaction or empowerment in rubrics, balancing clinical accuracy with communication quality. Global Standards: Collaborate with WHO or medical boards to create universal rubric frameworks, harmonising AI evaluation across countries. Real-Time Deployment: Embed rubrics in clinical workflows, allowing AI to self-assess and improve on the fly while maintaining human oversight. Rubric evaluations are poised to be the next frontier in healthcare AI by providing a rigorous, transparent and clinically grounded way to assess and improve LLMs. HealthBench’s physician validated rubrics demonstrate their value in ensuring AI is accurate, safe and equitable, but their potential extends far beyond current applications. By driving personalised care, regulatory compliance, and global collaboration, rubrics could unlock AI’s ability to transform healthcare > reducing errors, expanding access and supporting clinicians, while maintaining trust and accountability. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

NHS ConfedExpo 2025: What are the key talking points likely to be? NHS ConfedExpo 2025: What are the key talking points likely to be? The NHS ConfedExpo 2025, scheduled for June 11–12 at Manchester Central, is a flagship event for UK health and care leaders, organized by the NHS Confederation and NHS England. It will attract over 5,000 delegates to discuss transformative strategies for the NHS. Drawing on the 2025/26 Priorities and Operational Planning Guidance , the ICB Model Blueprint , and your interests in Polypills, cardiovascular innovation and backend automation, here are the key talking points likely to front and centre of mind for attendee's, updated to reflect the latest NHS guidance and funding context: 1. Digital Transformation and Funding Challenges Scaling digital health amidst financial constraints, aligning with the 10 Year Health Plan’s analogue-to-digital shift. Key Discussions: AI and Automation: Adoption of AI for backend processes like claims processing (e.g., Olive’s 98% accuracy), medical coding, and scheduling (e.g., Qventus’s OR optimisation), driven by the 2025/26 Guidance ’s 4% productivity target. Funding Gap: Addressing the £21 billion digitisation shortfall (per Health Foundation, May 2025) with only £4.9 billion in operational capital and £3.4 billion in prior tech funding. Sessions may explore private partnerships or Unified Tech Fund (UTF) expansion. Electronic Patient Records (EPRs): Achieving universal EPR coverage by March 2025, supported by £2 billion in multi-year funding, and integrating with the NHS App as the “digital front door.” Cybersecurity: Balancing investments in cyber resilience (funded nationally) with other digital priorities, given rising threats. Exhibitor Showcases: Companies like Graphnet Health and Viz.ai may demo Federated Data Platform (FDP) applications and AI diagnostics for cardiovascular care. The ICB Model Blueprint’s shift of digital responsibilities to providers will spark debates on equitable adoption, with ICBs leveraging FDP and UTF to meet productivity goals. 2. Prevention and Cardiovascular Innovation Shifting to proactive care models, emphasising primary prevention and community-based services.Key Discussions: Polypills: Scaling polypill use (e.g., CNIC-Polypill) for cardiovascular disease (CVD) prevention, supported by ICBs’ population health strategies in the 2025/26 Guidance . Polypills’ 33% mortality reduction and cost-effectiveness (0.2–2.8 days’ wages monthly) align with NHS equity goals. Wearables and AI Diagnostics: Integrating wearables (e.g., Masimo W1) and AI tools (e.g., MultiplAI Health’s RNA tests) for early CVD detection, funded through ICB allocations or UTF. Food-as-Medicine: Policy support for lifestyle interventions, inspired by global HealthTech trends, to reduce CVD burden. Case Studies: Initiatives like One Gloucestershire ICB’s prevention programs may highlight digital-enabled CVD care. The 10 Year Health Plan’s illness-to-prevention focus and ICB-led neighbourhood health models will drive discussions on affordable, scalable solutions like Polypills and 3D-printed medications. 3. Integrated Care and System Collaboration Strengthening Integrated Care Systems (ICBs and ICPs) to deliver seamless care across health, social care, and local government. Key Discussions: ICB Strategic Commissioning: The ICB Model Blueprint  positions ICBs as strategic planners, merging functions to optimise acute and primary care. Sessions will explore ICBs’ role in refreshing Joint Forward Plans by March 2025. Partnerships: Collaborations with local authorities and voluntary sectors to address social determinants, building on 2024’s Social Care Zone. Case Studies: North East North Cumbria ICB or Surrey Heartlands may showcase integrated pathways, potentially including polypill distribution. The 2025/26 Guidance emphasises shared outcomes under section 75 of the NHS Act, making integration a core ConfedExpo theme. 4. Workforce Sustainability and Wellbeing Tackling shortages, burnout, and training needs to support a resilient workforce. Key Discussions: Retention Strategies: Reducing agency costs by 30% and bank use by 10% (per 2025/26 Guidance ), alongside flexible working and international recruitment. Up-skillling for Digital: Training staff to use AI and automation tools, with CPD opportunities at the conference. Wellbeing: Addressing low staff morale (45% felt valued in 2023) through mental health support and workload reduction via automation. Case Studies: East Lancashire Hospitals NHS Trust’s reservist support may inspire workforce engagement models. The NHS workforce plan and ICB productivity targets will prioritise automation to ease administrative burdens, a key discussion point. 5. Health Inequalities and Population Health Reducing disparities through data-driven, equitable care delivery. Key Discussions: ICB-Led Equity: Using FDP and population health data to target deprived areas, as mandated by the 2025/26 Guidance . Only 20% of ICB leaders were confident in their equity strategies in 2023, signaling a focus area. Genomics and Biotech: Personalising care via genetic profiling, aligning with Matthew Taylor’s 2024 cancer treatment remarks. Social Determinants: Partnerships to address housing and education, critical for CVD prevention in underserved groups. The 10 Year Health Plan’s equity goals will amplify ICB-led initiatives, with Polypills as a cost-effective tool for high-risk populations. 6. Financial Sustainability and Efficiency Delivering value under tight budgets, with ICBs achieving breakeven positions. Key Discussions: Efficiency Targets: The 2025/26 Guidance ’s 4% productivity and 1% cost reduction goals drive automation and low-value activity cuts. Capital Constraints: With £4.9 billion operational capital and £750 million for estates safety, ICBs must prioritise high-ROI digital projects like FDP over new builds. Devolution Funding: South Yorkshire’s devolved model may inspire discussions on flexible funding. Social Value: Articulating the NHS’s £150 billion economic impact, a recurring ConfedExpo theme. Funding debates will explore bridging the £21 billion digitization gap, impacting automation and CVD innovation adoption. Final Thoughts NHS ConfedExpo 2025 will reflect the 2025/26 Priorities and Operational Planning Guidance and ICB Model Blueprint, emphasising digital transformation, prevention, and integration within a constrained £4.9 billion capital budget. Polypills and cardiovascular HealthTech will feature prominently in prevention talks, while backend automation (e.g., AI for claims, scheduling) will address productivity goals. Funding challenges, with a £21 billion digitisation gap, will drive debates on prioritising high-impact innovations. The event will align with the 10 Year Health Plan’s reform agenda, offering actionable insights for ICBs and providers. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025 Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.

What exactly is Consumer HealthTech? What exactly is Consumer HealthTech? Consumer HealthTech refers to digital tools and technologies that empower individuals to proactively manage their health and wellness. It includes mobile health apps, wearable devices (e.g., smartwatches, fitness trackers), telehealth platforms, and personalised wellness solutions, such as AI-driven diagnostics and digital biomarkers. The focus is on shifting healthcare from reactive treatment to preventive, consumer-driven care, enabling better health outcomes through accessibility, personalisation, and real-time monitoring. Here's a breakdown of the key aspects of Consumer HealthTech: Core Focus Empowerment of Individuals: Consumer HealthTech tools are designed for use by individuals themselves, giving them more control over their health journey.   Accessibility and Convenience: These technologies often aim to deliver health-related services and information outside of traditional healthcare settings, making them more convenient for users. Personalisation: Many Consumer HealthTech solutions leverage data and AI to provide tailored insights, recommendations, and interventions.   Proactive Health Management: A significant focus is on prevention, wellness, and self-management of health conditions rather than solely reactive treatment.   Examples of Consumer HealthTech Mobile Health Applications (mHealth): Apps for fitness tracking (e.g., Fitbit, Strava), nutrition and diet management (e.g., Noom), mental wellness (e.g., Headspace, Unmind), medication reminders, and chronic disease management. Wearable Devices: Smartwatches and fitness trackers (e.g., Apple Watch, Garmin, WHOOP) that monitor activity levels, sleep patterns, heart rate, blood oxygen, and other physiological data.   Telehealth Platforms: Services that enable virtual consultations with doctors and other healthcare providers via video calls or online chat (e.g., HealthHero, Ro).   Personalised Wellness Solutions: Platforms offering tailored nutrition plans, exercise programs, and lifestyle coaching based on individual data and goals (e.g., VITL, Zoe).   Remote Patient Monitoring (RPM) Devices: Tools that allow individuals to monitor their health conditions from home, such as blood glucose monitors (e.g., Dexcom), blood pressure cuffs, and connected scales.   Digital Therapeutics: Software-based treatments for medical conditions, often delivered through apps, that are designed to prevent, manage, or treat an illness or condition (though some may require a prescription).   At-home Diagnostics and Testing: Kits and platforms that allow individuals to collect samples and receive health information or connect with healthcare professionals remotely (e.g., Everly Health).   Mental Health and Well-being Platforms: Apps and online services offering tools for stress management, mindfulness, therapy, and support for mental health conditions (e.g., Lyra Health).   FemTech: Technologies focused on women's health needs, including fertility tracking (e.g., Flo Health), menstrual health, and menopause support.   AgeTech: Technologies designed to support the health and well-being of older adults.   Key Differences from Traditional Healthcare and MedTech User Focus: Consumer HealthTech primarily targets individual consumers, while traditional healthcare and MedTech often focus on healthcare providers and institutions. Setting: Consumer HealthTech solutions are often used at home or on the go, whereas traditional healthcare and MedTech are typically used in clinical settings. Purpose: While all aim to improve health outcomes, Consumer HealthTech places a greater emphasis on prevention, wellness, and self-management. MedTech focuses on tools for diagnosis and treatment by healthcare professionals.   In essence, Consumer HealthTech is about leveraging digital tools to put individuals at the centre of their own healthcare, promoting healthier lifestyles, improving access to information and services, and ultimately driving better health outcomes. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Continuous Glucose Monitoring - where is the evidence for CGM as a HealthTech sub market? Continuous Glucose Monitoring - where is the evidence for CGM? The continuous glucose monitoring (CGM) healthtech submarket is driven by a combination of clinical evidence, market growth data, and technological advancements, primarily for diabetes management but increasingly for broader health applications. Below is a breakdown of the evidence supporting the CGM market, drawn from clinical studies, market analyses and emerging trends. 1. Clinical Evidence for CGM in Diabetes Management CGM devices provide real-time glucose readings, improving glycemic control compared to traditional self-monitoring blood glucose (SMBG) methods. Key evidence includes: Improved Glycemic Control: Studies demonstrate CGM reduces HbA1c levels (a marker of long-term glucose control) and time spent in hypoglycemia. For example, a 2019 international consensus on CGM metrics highlighted correlations between time in target glucose range (70–180 mg/dL) and reduced diabetes complications, such as retinopathy and nephropathy. Reduced Hypoglycemia: CGM systems with alerts for low or high glucose levels help prevent severe hypoglycemic events, particularly in type 1 diabetes (T1D) and insulin-treated type 2 diabetes (T2D). Clinical trials show CGM users experience fewer hypoglycemic events compared to SMBG users. Integration with Insulin Delivery: CGM is critical for automated insulin delivery systems (e.g., hybrid closed-loop systems), which adjust insulin based on real-time glucose data. These systems have shown superior outcomes in T1D management, with evidence suggesting progress toward fully closed-loop "artificial pancreas" solutions. Adoption in Specific Populations: CGM is increasingly used in gestational diabetes and T2D, with studies showing better outcomes in HbA1c without increased hypoglycemia risk in these groups. For example, Abbott’s FreeStyle Libre has been approved for pregnant women with diabetes. Most high-quality evidence focuses on T1D and insulin-treated T2D. Evidence for CGM in non-insulin-treated T2D or non-diabetic populations is less robust, with studies often small-scale or industry-funded, raising concerns about bias. 2. Market Growth and Economic Evidence The CGM market is experiencing rapid expansion, driven by rising diabetes prevalence, technological innovation, and favourable reimbursement policies. Key data points include: Market Size and Projections: The global CGM market was valued at USD $4.6 billion in 2023 and is projected to grow at a CAGR of 7.19% through 2030. Another estimate suggests the CGM market could reach USD $16.8 billion by 2033 (CAGR 11.9%) or even USD 55 billion by 2035 (CAGR 15.7%). The broader blood glucose monitoring market, including CGM, is expected to hit USD $27.61 billion by 2032 (CAGR 8.29%). Drivers of Growth: Rising Diabetes Prevalence: The International Diabetes Federation estimates 643 million people will have diabetes by 2030, with obesity and aging populations as key contributors. Reimbursement Expansion: Policies like Medicare’s 2023 expansion of CGM coverage for insulin-using patients in the U.S. have boosted adoption. In England, 97% of T1D patients have access to CGM through the NHS. Technological Advancements: Innovations such as smaller sensors, longer wear times (e.g., 14-day sensors like Abbott’s FreeStyle Libre), and smartphone integration enhance user convenience and compliance. Regional Insights: North America dominates due to advanced healthcare infrastructure and high diabetes prevalence. Asia-Pacific is the fastest-growing region, driven by rising diabetes awareness, healthcare investments, and large populations in China and India. Market projections vary widely, reflecting uncertainty in adoption rates and regulatory changes. High costs (up to $300/month for non-diabetics) and limited reimbursement in low- and middle-income countries may constrain growth. 3. Technological Innovation and Industry Activity The CGM market is characterized by high innovation, with companies like Dexcom, Abbott, Medtronic, and Senseonics leading R&D efforts. Evidence of technological progress includes: Improved Accuracy and Convenience: Modern CGMs offer better sensor accuracy, reduced calibration needs, and real-time data sharing with healthcare providers. For example, Dexcom’s G7, cleared by the FDA in 2022, integrates with insulin pumps and supports pregnant women. Non-Invasive Trends: Emerging non-invasive CGM devices (e.g., GlucoRx’s multi-sensor system) and wearables like the K’Watch aim to reduce invasiveness, though most are still in clinical trials. AI and Predictive Analytics: Integration of AI and machine learning enhances predictive capabilities, enabling proactive diabetes management. Over-the-Counter Availability: The FDA’s 2024 approval of the first OTC CGM (Dexcom Stelo) for non-insulin users expands access to non-diabetics, potentially broadening the market. While innovation drives market enthusiasm, regulatory hurdles and high R&D costs create barriers for new entrants. Non-invasive technologies remain largely unproven in real-world settings, and their commercialisation timeline is uncertain. 4. Emerging Use in Non-Diabetic Populations CGM use among people not living with diabetes (PNLD) is growing, driven by wellness trends and claims of benefits like diet personalization and metabolic health optimization. However, evidence here is limited: Potential Benefits: Small studies and anecdotal reports suggest CGM can help PNLD identify glucose spikes from diet or lifestyle, potentially improving energy, sleep, or mood. A University of Tokyo study indicated CGM may detect early diabetes risk more accurately than blood tests in healthy adults. Skepticism and Risks: A 2025 narrative review found “no consistent high-quality evidence” supporting CGM in PNLD, citing risks of maladaptive dietary changes (e.g., avoiding healthy foods like whole grains due to glucose spikes). Marketing claims often outpace evidence, raising concerns about misinformation. Prevalence of Abnormal Glucose: A study of over 5,000 “healthy” adults where 43% showed pre-diabetes or diabetes-level glucose via CGM, suggesting potential for early detection but lacking peer-reviewed confirmation. The PNLD market is speculative, with commercial interests potentially inflating benefits. Regulatory oversight is inadequate for off-label use, and psychological impacts (e.g., fixation on glucose levels) are understudied. 5. Challenges and Gaps in Evidence Despite strong evidence for CGM in diabetes, several gaps and challenges persist: Cost and Access: High costs and limited reimbursement in low- and middle-income countries restrict access. Even in high-income regions, CGM is not universally covered for non-insulin users. Regulatory Barriers: Stringent FDA and EMA requirements ensure safety but delay market entry for new devices. Data Standardisation: Lack of standardised CGM metrics and reporting hinders clinical adoption and interoperability. Long-Term Outcomes: Most studies focus on short-term metrics (e.g., HbA1c, time- Long-Term Outcomes: Long-term trials linking CGM metrics to complications like retinopathy are suggestive but not definitive, limiting claims of preventing chronic issues. Non-Diabetic Use: Evidence for CGM in PNLD is weak, with commercial claims potentially misleading. Psychological Impact: Excessive monitoring may lead to anxiety or disordered eating, especially in PNLD, but this is under-researched. The CGM healthtech submarket is well-supported by evidence for diabetes management, particularly for T1D and insulin-treated T2D, with robust clinical data showing improved glycemic control, reduced hypoglycemia, and integration with insulin delivery systems. Market growth is strong, driven by rising diabetes prevalence, reimbursement expansion, and technological advancements, with projections estimating significant revenue increases by 2030–2035. However, evidence for non-diabetic use is sparse and controversial, with risks of misinformation and psychological harm. While CGM is a transformative tool for diabetes, its broader application requires more rigorous research to validate claims and address access disparities. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Neighbourhood Health: What do HealthTech suppliers need to think about following the recent ICB National Footprint guidance? Neighbourhood Health: What do HealthTech suppliers need to think about following the recent ICB National Footprint guidance? The recent NHS England Neighbourhood Health guidelines for 2025/26 outline a strategic direction that significantly impacts HealthTech suppliers aiming to provide solutions within the English healthcare system. This guidance emphasises a fundamental shift in how healthcare is delivered, moving towards more integrated, proactive, and community-based models. For HealthTech suppliers, understanding the nuances of this approach is crucial for developing relevant solutions and navigating the procurement and adoption landscape.   The core concept of Neighbourhood Health revolves around delivering care closer to people's homes, strengthening primary and community services, and fostering integrated working among multidisciplinary teams (MDTs) at a local level. This is part of a broader government ambition to shift from a reactive, hospital-centric model to a more preventative and community-oriented healthcare system, heavily reliant on digital transformation. The recent NHS Integrated Care Board (ICB) national footprint guidance, particularly the Neighbourhood Health Guidelines 2025/26, shifts the focus toward integrated, community-based care, impacting HealthTech suppliers in the UK. Here’s what suppliers need to consider: Alignment with Neighbourhood Health Priorities The guidance emphasises delivering care closer to home through integrated neighbourhood teams (INTs), focusing on population health and reducing inequalities. HealthTech suppliers must ensure their solutions support proactive, planned, and responsive care for complex needs, such as social prescribing or comprehensive geriatric assessments. Products should address local population health challenges, like managing long-term conditions or preventing hospital admissions. Interoperability and Data Integration The guidelines stress the importance of compatible clinical data systems across GP, social care, and other providers. Suppliers need to prioritise interoperability, ensuring their technologies integrate seamlessly with existing NHS systems, such as the Federated Data Platform (FDP), which 85% of secondary care trusts are expected to adopt by March 2026. Solutions should also support population health management, like risk stratification, to align with upcoming NHS data guidance in 2025. Collaboration with Local Stakeholders ICBs, local authorities, and voluntary sector partners are tasked with co-designing neighbourhood health models. Suppliers must engage early with these stakeholders, including primary care networks and place-based partnerships, to co-produce solutions tailored to local needs. Building relationships at the neighbourhood level, rather than relying solely on centralised ICB procurement, is critical. Focus on Health Inequalities The guidance mandates tackling health disparities, ensuring accessibility for underserved groups (e.g., by disability, ethnicity, or deprivation). Suppliers should design inclusive technologies, incorporating features like multilingual support or accessibility adjustments, and provide evidence of how their solutions reduce inequalities, a key metric for ICB evaluation. Support for Step-Up and Step-Down Care The emphasis on efficient step-up (preventing admissions) and step-down (timely discharges) pathways means suppliers should offer solutions that optimise resource use, such as remote monitoring or virtual wards. Technologies that enable seamless transitions between care settings, like home-first approaches, will be prioritised. Sustainability and Net Zero Compliance ICBs are bound by the NHS’s net zero targets, reinforced by the Health and Care Act 2022. Suppliers must align with the NHS Net Zero Supplier Roadmap: by April 2027, all suppliers need to report global Scope 1, 2, and 3 emissions, and by April 2028, provide carbon footprints for individual products. Immediate steps include preparing Carbon Reduction Plans (CRPs) for contracts over £5 million per annum, a requirement since April 2023. Value-Based Procurement (VBP) Opportunities Upcoming VBP guidance in 2025 will evaluate technologies on financial, efficiency, patient, and environmental benefits, not just cost. Suppliers should highlight broader value, such as improved outcomes or reduced secondary care referrals, as seen in the Tower Hamlets Women’s Health Hub model, which cut secondary care referrals by 60%. Adapting to Devolved Decision-Making Recent industry commentary indicates a potential shift in ICB roles from operational to strategic commissioning, with providers gaining more tech decision-making power. Suppliers may need to target individual NHS trusts and place-based partnerships directly, tailoring pitches to local footprints while navigating potential inconsistencies in adoption across the 42 ICBs. While the guidance promotes integration and local flexibility, it risks creating a fragmented market where suppliers face inconsistent adoption and varying priorities across neighbourhoods. The permissive nature of the guidelines, allowing local tailoring, may disadvantage smaller HealthTech firms lacking resources to engage multiple stakeholders. Additionally, the NHS’s slow adoption history and budget constraints could hinder the promised “revolution in access to care,” such as the target for 70% of elective appointments to be managed via the NHS App by 2025. Suppliers should remain skeptical of over-optimistic timelines and focus on building robust, evidence-based cases for their solutions’ impact on productivity and patient outcomes. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025 Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America

Nelson Advisors partner Lloyd Price and a panel of HealthTech CEO's and Founders debated a range of topics at The Future Health event in Leeds on Thursday 8th May with former Health Secretary Matt Hancock. A number of points were made by the panel including the need for a centralised ‘Kitemark’ for evidence standards across providers, the need for suppliers to have a clear route to commercialisation in what is a very complex and challenging landscape, as well as the need to allow procurement to be open and competitive to all suppliers. In addition, other points of interest in the discussions and debate included: - Digital fatigue: Clinicians overwhelmed by tech that doesn’t ease their workload. - Collaboration over competition: Heather emphasized there’s ample opportunity for all—no need for a scarcity mindset. - Integrated solutions: Mike Sanders highlighted the necessity for companies to work together, offering a comprehensive view of capacity. - Evidence-based adoption: Lloyd stressed the importance of robust evidence for new technologies to gain trust and traction. The Future Health The Future Health event series brings the community together through various formats, including webinars, workshops, and conferences. These events provide invaluable opportunities for networking, knowledge sharing, and partnership development. Attendees can engage with industry leaders, participate in interactive sessions, and gain practical insights to drive their businesses forward. Future Health, a global community of health tech leaders, organised the gathering as part of a series of events that explore the latest ideas, people, innovations, and technologies shaping healthcare's future. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Polypills and Cardiovascular Innovation: HealthTech market to watch in 2025 Polypills and Cardiovascular Innovation: HealthTech market to watch in 2025 The HealthTech market for cardiovascular innovation, particularly Polypills, is poised for significant growth in 2025, driven by rising cardiovascular disease (CVD) prevalence, advancements in digital health, and increasing emphasis on preventive care. Below is a comprehensive analysis of Polypills and the broader cardiovascular HealthTech landscape, highlighting key trends, market drivers, challenges, and innovations to watch in 2025. Polypills: A Game-Changer for Cardiovascular Care What Are Polypills? Polypills are fixed-dose combination (FDC) medications that combine multiple active pharmaceutical ingredients, typically a statin (for cholesterol management), an antihypertensive (for blood pressure control) and an antiplatelet agent (eg low-dose aspirin) into a single pill. Designed to improve adherence and simplify treatment regimens, polypills address both primary and secondary prevention of CVD. The concept, introduced by Wald and Law in 2003, aims to reduce cardiovascular events by enhancing patient compliance and reducing healthcare costs. Clinical Impact and Evidence Efficacy: Clinical trials, such as the SECURE trial, have demonstrated that polypills (eg. CNIC-Polypill containing aspirin, ramipril and atorvastatin) reduce cardiovascular mortality by 33% in patients post-myocardial infarction. They significantly lower blood pressure, LDL cholesterol and major adverse cardiovascular events (MACE). Adherence: Polypills address poor adherence, a major barrier to CVD management, with studies showing fewer than 50% of patients consistently follow multi-drug regimens. By simplifying dosing, Polypills improve compliance, particularly in high-risk populations. Cost-Effectiveness: Polypills are often more affordable than multiple individual medications, with studies like the one by Van Gils et al. showing reduced healthcare costs and improved quality-adjusted life years (QALYs) in high-risk populations. Market Availability and Challenges Availability: Polypills are approved in select countries (eg. Spain, India, Mauritius, Argentina) with the CNIC-Polypill being the only one approved by the European Medicines Agency for primary and secondary CVD prevention. However, global availability remains limited, particularly in public-sector pharmacies and Polypills are often absent from national guidelines or formularies. Affordability: In countries like India and Spain, Polypills are relatively affordable (0.2–2.8 days’ wages for a month’s supply for the lowest-paid workers) but high costs in other regions and lack of local manufacturing hinder accessibility. Challenges: Physician hesitancy, inability to tailor doses, safety concerns and patent expirations (eg. generic versions of drugs like Vytorin) pose barriers to widespread adoption. Additionally, cultural perceptions of CVD as a lifestyle condition may limit investment in polypill strategies. Market Outlook for Polypills in 2025 The global polypill products market is projected to grow at a CAGR of ~2% through 2027, reaching ~US$35 Billion, driven by rising CVD prevalence and R&D into safer, more effective formulations. Innovations like 3D-printed Polypills, which allow precise control over drug release, are gaining traction and could enhance personalisation. Increased inclusion in guidelines (eg. 2023 European Society of Cardiology recommendations) and advocacy from organisations like the World Heart Federation will likely boost adoption. Focus areas for 2025 include improving affordability through generic production, expanding regulatory approvals, and integrating Polypills into national health systems, particularly in low and middle income countries (LMICs). Cardiovascular HealthTech Market: Broader Innovations The cardiovascular HealthTech market is experiencing rapid growth, with digital health, medical devices, and diagnostic platforms transforming CVD prevention, diagnosis and management. The global digital health market for cardiovascular care was valued at USD $42.42 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030, reaching USD $140.96 billion by 2030. Key Drivers Rising CVD Prevalence: CVD remains the leading cause of death globally, with 18.6 million deaths in 2019, driving demand for innovative solutions. Technological Advancements: AI, machine learning (ML), wearables, and Telehealth are revolutionising CVD care by enabling early detection, remote monitoring, and personalised treatment. Demand for Preventive Care: Growing awareness of cardiovascular health and policy support (eg. Medicare Advantage coverage for food-as-medicine programs) are shifting focus to prevention. Aging Population: The global elderly population, particularly in Asia Pacific (projected to reach 1.2 billion by 2050), increases the need for scalable CVD solutions. Innovations to Watch in 2025 Digital Health and Software Wearables and Sensors: Next-generation wearables (eg. Apple AirPods with biometric sensors, Masimo W1 health tracking watch) monitor heart rate, blood pressure, and other metrics in real time. These devices are expanding into areas like cardiovascular risk assessment but face challenges in securing reimbursement. AI-Powered Diagnostics: Companies like MultiplAI Health use AI and RNA-based blood tests to detect subclinical CVD, offering up to 35% better performance than traditional risk calculators. Similarly, Viz.ai and Cleerly leverage AI for imaging-based diagnostics. Telehealth Platforms: Virtual care platforms for chronic disease management (e.g., Omada, Hello Heart) are gaining traction, with Telehealth market growth projected at a CAGR of 24.5% through 2033. Medical Devices Minimally Invasive Technologies: Devices like Boston Scientific’s FARAPULSE PFA System and FARAWAVE NAV Ablation Catheter are advancing cardiac ablation for arrhythmias, improving outcomes with less invasive procedures. Bioresorbable Stents and Wearable Monitors: Innovations in bioresorbable stents and ambulatory ECG monitors (eg. Peerbridge Health’s Cor) enhance diagnostics and treatment precision. Market Growth: The cardiovascular devices market is HR is projected to grow at a CAGR of 8.4% from 2025 to 2030, reaching USD $86.36 billion by 2030. Diagnostic Platforms Precision Diagnostics: Platforms like Anumana and Ultromics use AI to analyse ECGs and ultrasounds, improving early detection of conditions like atherosclerosis and heart failure. Patient Phenotyping and Digital Twins: AI-driven patient phenotyping and digital twins are emerging for personalised care and optimised clinical trial designs, though still in nascent stages. Drug Repurposing and Combination Therapies Repurposed Drugs: SGLT-2 inhibitors (eg. Jardiance) originally for diabetes are now approved for heart failure, demonstrating significant cardiovascular benefits. New Drug Launches: In 2024–2025, drugs like Bayer’s Acoramidis (for Transthyretin Amyloid Cardiomyopathy) and generic Rivaroxaban (Anticoagulant) are expanding treatment options. Accelerators and Investments HeartX Accelerator: The HeartX program, run by HealthTech Arkansas and MedAxiom, will select five early-stage cardiovascular startups in 2025, offering $150,000 in funding and guaranteed pilot projects. This initiative underscores the focus on bridging innovation to clinical validation. Venture Capital: Despite a 31% decline in funding for cardiovascular digital health ventures from 2021 to 2022 ($3.4 billion in 2022), renewed investor interest and improving capital market conditions are expected to drive growth in 2025. Challenges in Cardiovascular HealthTech Reimbursement Barriers: Wearables and digital health solutions struggle to secure traditional healthcare reimbursement, though Medicare Advantage and HSA eligibility may open doors. Data Privacy and Security: AI-driven solutions require robust data management to ensure patient privacy, especially with healthcare data cooperatives. Market Consolidation: The healthcare AI market is consolidating, with Big Tech (e.g., Epic, Oracle) and established players dominating, making it harder for startups to compete. Regulatory Hurdles: Innovations like multipurpose polypills and AI diagnostics face complex regulatory pathways, particularly in the U.S., where the FDA has not approved a multipurpose polypill. Key Players and Collaborations Pharmaceuticals: Bristol-Myers Squibb, Pfizer, Bayer, AstraZeneca, Novartis, and Sanofi are leading in cardiovascular drugs and polypill development. HealthTech: Withings, Eko, AliveCor, HeartFlow, Viz.ai , Cleerly, and MultiplAI Health are driving digital health and diagnostics. Collaborations: Partnerships like Veradigm-HealthVerity (real-world data research), Philips-Masimo (telehealth), and American College of Cardiology-Serv Medical (digital care innovation) are accelerating progress. Trends to Watch in 2025 Integration of AI and Digital Health: AI will shift from experimental to clinically validated applications, with predictive triage systems combining patient data and real-time metrics for proactive care. Focus on Prevention: Polypills, wearables, and food-as-medicine programs will emphasise primary prevention, supported by policy incentives like Medicare Advantage expansions. Personalised Medicine: Advances in patient Phenotyping, digital twins, and 3D-printed Polypills will enable tailored treatments, though scalability remains a challenge. Global Expansion: Asia Pacific will lead growth in cardiovascular drugs and devices due to its aging population and healthcare investments, while LMICs will prioritise affordable Polypills. Sustainability and Equity: HealthTech will focus on equitable access, with innovations like low-cost polypills and telehealth addressing disparities in CVD care. In 2025, Polypills and cardiovascular HealthTech will be critical areas to watch, driven by the urgent need to address CVD’s global burden. Polypills offer a proven, cost-effective solution to improve adherence and reduce events, but their adoption hinges on overcoming availability, affordability, and regulatory challenges. Meanwhile, the broader HealthTech market, spanning AI diagnostics, wearables, minimally invasive devices, and drug repurposing, is set for explosive growth, with a projected CAGR of 22.5% for digital health. Stakeholders must prioritise reimbursement models, data security, and equitable access to ensure these innovations reach their full potential. By blending pharmacological advances like polypills with cutting-edge digital tools, 2025 could mark a transformative year for cardiovascular care. Nelson Advisors > Healthcare Technology M&A . Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025

Red Flags for Acquirers in todays HealthTech market Red Flags for Acquirers in todays HealthTech market In today’s HealthTech market, strategic acquirers are highly cautious due to economic pressures, the rise of distressed M&A and a focus on financial discipline. Founder dynamics and cap table issues can significantly deter potential acquirers, especially given the sector’s current challenges like company debt and lack of profitability. Here are the main red flags Nelson Advisors see week in and week out from strategic acquirers:: Founder Red Flags Lack of Commitment or Misalignment Founders who appear disengaged or lack a clear long-term vision for the healthtech company raise concerns. Acquirers want founders who are fully committed to driving post-acquisition growth, especially since many healthtech firms require significant integration efforts. A founder with a part-time focus or who has already mentally checked out signals risk. Misalignment with the acquirer’s goals, such as differing views on value-based care or innovation priorities (e.g., AI, telehealth), can stall deals. Acquirers seek founders whose vision complements their strategic objectives, like improving patient outcomes or reducing costs. High Turnover or Team Imbalance High turnover among key team members, especially early on, suggests a toxic culture or poor leadership—both of which can derail post-acquisition integration. Acquirers look for stable, talented teams with experience in navigating healthcare’s complex regulatory and operational landscape. An imbalanced founding team, such as one lacking technical expertise (e.g., no CTO in a tech-driven healthtech firm) or business acumen, is a red flag. For example, a team of only business founders raising funds to hire a scientist lacks the technical credibility needed for healthtech innovation. Overcontrol or Governance Issues Founders retaining excessive equity (eg, 70%+ at later stages) signal an unwillingness to share control, which can limit the acquirer’s ability to influence strategy. This is particularly concerning in healthtech, where acquirers often need to integrate the target into broader operations or pivot technologies. Poor governance, such as lack of transparency during due diligence or unresponsive behavior, suggests potential integrity issues. Acquirers need founders who are open and collaborative to ensure a smooth acquisition process. Cap Table Red Flags Broken or Overly Complex Cap Table A “broken” cap table, where founders hold too little equity (eg. under 20% post-Series A) and investors dominate, indicates over-dilution. This can demotivate founders, reducing their drive to execute post-acquisition, which is a major concern for acquirers expecting founder-led growth. Over complication, such as having numerous small investors (e.g., dozens of angels each with <1% stakes), creates logistical nightmares. In healthtech, where quick decision-making is critical due to regulatory and market pressures, a fragmented cap table can hinder consensus and agility, making the company less attractive. Disproportionate Investor Shares or Debt If early investors hold disproportionately large equity (e.g., 50%+ from seed rounds), it suggests overvaluation in past rounds, a red flag for acquirers wary of inflated valuations in a market where multiples have compressed to 4-6x revenue (March 2025 data). This also leaves little room for the acquirer to gain meaningful ownership without heavy dilution of others. Significant debt on the cap table, especially if used to “save the business” rather than scale, is a dealbreaker. Healthtech acquirers in 2025 are already cautious about funding unprofitable firms, and taking on debt further erodes their willingness to pay. Inactive Stakeholders or Unclear IP Ownership Equity held by inactive stakeholders, like ex-founders or early friends-and-family investors who no longer add value, complicates governance. For instance, an ex-founder with 20% equity but no role can create power struggles, deterring acquirers who need clear control to integrate the company. Unclear intellectual property (IP) rights tied to the cap table, such as IP owned by a founder’s separate entity, are a major issue in healthtech. Acquirers prioritise strong IP portfolios (e.g., in AI or genomics) to protect innovations, and any ambiguity can kill a deal. Why These Matter in Today’s Healthtech Market Economic Caution: With healthtech M&A multiples at 4-6x revenue and distressed deals on the rise, acquirers are prioritising financial stability. A messy cap table or uncommitted founders amplify the risk of overpaying for a company that can’t deliver synergies. Strategic Fit: Acquirers seek healthtech firms with disruptive technologies (eg., AI, telehealth) and strong teams to drive value-based care. Founder misalignment or governance issues make integration harder, especially in a market focused on cost reduction and patient outcomes. Shareholder Pressure: Acquirers face pressure to deliver value to their shareholders. A healthtech target with red flags like high debt, overcontrol, or a fragmented cap table increases the risk of value destruction, making acquirers hesitant to proceed. In the 2025 healthtech market, acquirers are on high alert for founder and cap table red flags that signal risk or complicate integration. Founders with excessive control, imbalanced teams, or lack of commitment, paired with cap tables that are over-diluted, debt-heavy, or overly complex, can scare off buyers. Healthtech companies must maintain clean, balanced cap tables and demonstrate strong, aligned leadership to attract strategic acquirers in this cautious environment. Nelson Advisors > HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   We work with our clients to assess whether they should 'Build, Buy, Partner or Sell' in order to maximise shareholder value and investment returns. Email  lloyd@nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     #HealthTech   #DigitalHealth   #HealthIT   #NelsonAdvisors   #Mergers   #Acquisitions   #Growth   #Strategy   #Cybersecurity   #HealthcareAI   #Partnerships   #NHS   #UK   #Europe   #USA   #Canada Nelson Advisors   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk   Meet Us   Digital Health Rewired > 18-19th March 2025    NHS ConfedExpo  > 11-12th June 2025   HLTH Europe > 16-19th June 2025   HIMSS AI in Healthcare > 10-11th July 2025